The primary immunodeficiencies are attractive candidates for the development of gene therapy approaches based on the transduction of hematopoietic cells. We have constructed a high-titer recombinant retrovirus for expression of gp9l-phox, deficiencies of which cause the X-linked form of chronic granulomatous disease (X-CGD). We have used this vector to transduce human bone marrow, using either unfractionated mononuclear cells or purified CD34+ cells as targets and evaluated several infection protocols. Efficient gene transfer to progenitors and long-term culture-initiating cells (LTC-IC) was obtained for each target population. Im-ENE TRANSFER TO the totipotent bone marrow stem G cell offers an attractive possibility for a gene therapy approach to the management of inherited diseases of the hematopoietic system. Potentially, any disease for which bone marrow transplantation (BMT) is curative would be amenable. The primary immunodeficiencies are good examples as the manifestation of disease is restricted to the hematopoietic system and BMT, when appropriately matched donors are available, can be curative.' In this regard, severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) has been widely Metabolic diseases, such as the lysosomal storage diseases, have also been the focus of some attention for gene delivery to hematopoietic cells, although the neurological aspects of such diseases are not likely to be corrected by this route.'.'" A further possibility is to use gene transfer to hematopoietic stem cells as an adjunct to other conventional therapy, such as expression of the multidrug resistance gene mdr to confer greater resistance to the ablative effects of chemotherapy for the treatment of cancer." The first hurdle to be overcome for any of these gene therapy approaches is delivery of genetic material to the hematopoietic stem cells and techniques for achieving this will be widely applicable.
G cell offers an attractive possibility for a gene therapy approach to the management of inherited diseases of the hematopoietic system. Potentially, any disease for which bone marrow transplantation (BMT) is curative would be amenable. The primary immunodeficiencies are good examples as the manifestation of disease is restricted to the hematopoietic system and BMT, when appropriately matched donors are available, can be curative.' In this regard, severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) has been widely Metabolic diseases, such as the lysosomal storage diseases, have also been the focus of some attention for gene delivery to hematopoietic cells, although the neurological aspects of such diseases are not likely to be corrected by this route.'.'" A further possibility is to use gene transfer to hematopoietic stem cells as an adjunct to other conventional therapy, such as expression of the multidrug resistance gene mdr to confer greater resistance to the ablative effects of chemotherapy for the treatment of cancer." The first hurdle to be overcome for any of these gene therapy approaches is delivery of genetic material to the hematopoietic stem cells and techniques for achieving this will be widely applicable.
Chronic granulomatous disease (CGD) is a deficiency of neutrophils and macrophages due to the failure of the phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase to produce 0,. ' of the disease (X-CGD) results from mutations in the gene encoding gp91-phux, the large subunit of the NADPH oxidase transmembrane cytochrome, and accounts for two thirds of patients. Current clinical management of CGD involves administration of prophylactic antibiotics. Nevertheless, there is still a 50% mortality rate by the age of 20 years."
BMT can offer a satisfactory cure, although it has not been widely used. We,I4.I5 and others,lh-19 have previously used Epstein-Barr virus transformed B-cell lines derived from patients with X-CGD or autosomal CGD (A-CGD), which model the disease in vitro,20 as targets for gene delivery of several of the NADPH oxidase components and demonstrated restoration of activity in such cells. More recently, correction has been achieved in patient peripheral blood progenitor cells."~2z Thus, there is reason to believe that gene therapy for CGD by transfer of the cDNA for the defective component to the hematopoietic stem cell could lead to functional reconstitution of derived phagocytic cells. We have developed a gene therapy approach for X-CGD using recombinant retroviral vectors for the transduction of human bone marrow.
The principle of retroviral transduction of bone marrow stem cells has been established in the murine system. The ability to reconstitute lethally irradiated mice with transduced marrow cells and detect marked cells in all hematopoietic lineages has been demonstrated. That transduction involves the stem cell compartment was confirmed by successful bone marrow reconstitution of secondary recipients (see, for examples, references 3 and 23). The majority of such experiments have used target bone marrow cells derived from animals pretreated with 5-fluorouracil (5-FU) to stimulate stem cell cycling. The advantage of this treatment presumably reflects the requirement for cell proliferation for integration of the retroviral vectors Some investigators have reported that prestimulation of the target cells enhances tran~duction,~ for which the combination of the cytokines interleukin (IL)-3 and IL-6 was optimaLZ5 IL-3 and IL-6 have been used in experiments with human bone marrow in similar p r o t~c o l s .~*~~*~~*~ Other cytokine combinations have also been used,2'~22~28 and some studies have included p r e s t i m u l a t i~n . "~'~~~~~~ However, the importance of such parameters initially described in the murine system remains to be examined for the transduction of human bone marrow cells.
CD34 is a marker of a population comprising approximately 1% of bone marrow cells that contains both progenitor and reconstituting stem cells?' CD34+ cells derived from bone marrow or peripheral blood appear to be as transducible as unfractionated cells.'330 Clinical scale-up of a gene therapy approach would be greatly facilitated by the use of such an enriched target cell population. We have demonstrated efficient gene transfer to human bone marrow progenitors of all lineages and long-term culture-initiating cells (LTCICs) using either unfractionated mononuclear cells or CD34' cells as targets for infection with a recombinant retrovirus vector expressing gp9 1-phon. Partial reconstitution of NADPH oxidase activity was obtained following transduction of X-CGD bone marrow cells.
MATERIALS AND METHODS
The retrovirus MFGcgd was generated from the amphotropic packaging cell line GP + en~-Am12~' following CaP04-mediated cotransfection with pSV2neo and selection of a high-titer producer cell clone (lo5 particleslml). The plasmid was constructed by insertion of the gp91-phox CDNA'~ into the BamHI site of the vector PMFG.~' In some experiments, a cell line of similar titer producing the virus MFGnlslacz, encoding nuclear localized &galactosidase, was used.33 For infection with cell-free virus, confluent cells were grown for 24 hours in long-term bone marrow culture (LTBMC) medium (see below), and the supematant was filtered (0.45 pm) for immediate use. Viruses were determined to be helper-free using a marker rescue assay.% Filtered supematant was added to a 3T3 cell line harboring multiple copies of the provirus MFGnlslacz. These cells were passaged for 10 days to allow for propagation of any replication competent virus. The supematant was filtered and used to infect 3T3 cells that were histochemically stained 48 hours later for P-galactosidase expression resulting from provirus rescue.
Bone marrow was obtained under local anesthetic from the posterior iliac crest of healthy adult volunteers following informed consent and appropriate ethical approval. Samples were similarly obtained from two X-CGD patients (S.W. and A.H.) while under general anesthesia for other operative procedures. The mononuclear cell fraction was prepared by density separation over Ficoll-Paque. LTBMCs were established with lo7 mononuclear cells in 25 cm2 flasks in 10 mL medium (McCoy's 5A supplemented with 12.5% fetal calf serum (FCS), 12.5% horse serum, 0.075% sodium bicarbonate, 1 mmoVL sodium pyruvate, 2 mmovL glutamine, minimum essential medium (MEM) amino acids and vitamins, 280 ng/mL hydrocortisone, 100 U/mL penicillin, 100 pg/mL streptomycin, and 250 ng/mL amphotericin B) and incubated at 37"C, 5% CO,. Cultures were fed at weekly intervals by replacement of half of the medium. An extensive stromal cell layer formed within 2 weeks in such cultures. When required for support of transduced bone marrow mononuclear or CD34' cells, established stromal layers were gamma-irradiated ("'Cs source, 2,000 rad).
The CD34+ bone marrow fraction was obtained from the mononuclear cell fraction by negative selection with soybean agglutinin followed by positive selection using ICH3 CD34 monoclonal antibody (MoAb)-coated CELLector flasks according to the manufacturer's instructions (Applied Immune Sciences Inc, Menlo Park, CA). The purity was >90% by fluorescence-activated cell sorter (FACS) analysis following staining with the CD34 MoAb 8G12 conjugated to fluorescein isothiocyanate (FITC), and cell yields were 0.5% to 2.0% of the mononuclear cells.
The colony-forming potential of bone mmom glutamine, 50 pmol/L 2-mercaptoethanol, 1 mg/mL bovine serum albumin (BSA), 1.7 U/mL IL-3, 10 U/mL IL-6, 3.3 U/mL granulocyte-colony stimulating factor (G-CSF), 2 U/mL erythropoietin, and 6 ng/mL stem cell factor (SCF). Cultures were incubated at 3 7 T , 5% C02, and colonies were scored 2 to 3 weeks later according to morphology. The standard protocol used in this study was to coculture 5 X IO6 mononuclear cells in a 25-cm2 flask containing a preformed confluent layer of retrovirus producer cells. Before addition of the target cells, the producer cell layer was gamma-irradiated (I3'Cs source, 2,000 rad). Coculture conditions were as described for LTBMC, but with the addition of 10 U/mL IL-3, 200 U/mL IL-6 (both recombinant human cytokines, from Boehringer Mannheim UK, Lewes, UK) and 2 pg/mL polybrene. After 4 days the nonadherent cells were removed and assayed for progenitors. Using MFGnlslacz, we determined that the virus titer on 3T3 cells from irradiated producer cells was maintained for at least the duration of the experiment. Variations of this protocol were tested: when used, recombinant human SCF (Sigma Chemical Co Ltd, Poole, Dorset, UK) was at 10 ng/mL. In some experiments, infected cells were transferred to flasks containing irradiated heterologous stromal cell layers for maintenance in LTBMC. Progenitors giving rise to colonies after 5 weeks in LTBMC were used as an assay for LTC-IC.36 Supematants from cultures of infected bone marrow cells after 5 weeks LTBMC were negative for helper virus.
Purified CD34+ cells were transduced in several ways. A total of 2 X lo5 cells were cocultured with retrovirus producer cells as for unfractionated mononuclear cells. For use of cell-free virus, 2 X lo5 cells were incubated ovemight in 10 mL LTBMC medium in a 25-cm2 flask with an irradiated heterologous stromal cell layer and infected six times over 4 days by removal of 5 mL medium and replacement of the cells in 5 mL virus. Polybrene was included at 2 pg/mL. The effect of IL-3 (10 U/mL) and IL-6 (200 U/mL) was examined, in which case the cytokines were replenished at each infection cycle. Following infection, the nonadherent cells were used for progenitor assay. In some experiments, infected cells were maintained in LTBMC, as above. Additionally, CD34+ cells were infected in 6-well plates using the Transwell system (Costar UK, High Wycombe, UK) by culturing them within the insert suspended above a producer cell layer, but separated by means of a 0.45 pm membrane. The producer cells were irradiated, trypsinized and seeded into the lower chamber to form a confluent layer. A total of 2 X lo4 to 2 x 10s CD34+ cells were added to the upper chamber. The total volume of culture medium, containing 2 pg/mL polybrene, was 5 mL. The effect of 10 U/mL IL-3 and 200 UlmL IL-6, or 10 ng/mL SCF in addition to IL-3nL-6, was examined. After 4 days, the cells from the upper chamber were used for progenitor assay.
Individual well-separated colonies were picked from the methylcellulose medium and flushed into phosphate buffered saline. The cells were pelleted, resuspended in 50 pL lysis buffer (50 mmom Tris.HC1, pH 8.0,l mmoV L EDTA, 0.5% Tween-20, 200 pg/mL proteinase K) and incubated at 55°C for 1 hour. Lysates were heated to 95°C for 10 minutes, and 20 pL was used for polymerase chain reaction (PCR) analysis. Typically, 20 to 30 colonies for each experimental variation were assayed in this way. Duplex PCR was performed, using one primer pair to detect the integrated provirus and a second to amplify part The amplification cycle was 30 seconds at 94"C, 1 minute at 57"C, 1 minute at 7 2 T , and products were separated by electrophoresis in 2% agarose gels. The control MBP product was visible by ethidium bromide staining, but the provirus product was detected by Southern blotting. Colonies giving weak signals despite abundant control product were not regarded as positive. In some experiments, in which target cells had been in direct contact with virus-producing cells, PCR was applied to provirus-positive samples using primers for the hygromycin resistance gene (hygro"), a component of one of the plasmids used to generate the packaging cell line GP + en~-Am12.~'
The hygro" primers were 5'-AAGCCTGAACTCACCGCGAC and 5'-GGTCAAGACCAATGCGGAGC, giving an 81 1-bp product.
Colony lysates prepared as above were used for inverse PCR amplification of sequences 3' of the provirus integration site. The target DNA was first rendered double-stranded by extending from the forward primer 5'-GAGGAGAAAGATGTGATCACAGG, upstream of the final intron of the endogenous gene and beginning at position 1503 of the gp91-phox cDNA within the provirus. A total of 20 pL lysate was incubated in a 50-pL reaction containing 50 mmol/L Tris.HC1, pH 7.2, I O mmol/L MgSO,, 0.1 mmoVL dithiothreitol (DTT), 50 pg/mL BSA, 40 pmoVL dNTPs, 50 pmol primer and 1 U DNA polymerase I Klenow fragment, and incubated at 37°C for 1 hour. The enzyme was denatured for 10 minutes at 70°C. and the products were digested in a total volume of 70 pL with 6 U ApoI, for 3 hours at 50°C. ApoI cuts the gp91-phox cDNA at position 1569, but there are no sites 3' of this within the MFGcgd provirus: the next site is thus at a variable distance within flanking DNA (averaging 1 kb). The DNA was purified using Geneclean, eluted, and ligated overnight at 16°C in a 10-pL reaction containing 66 mmovL Tris.HC1, pH 7.5.5 mmol/ L MgClz, 1 mmoVL DTT, 1 mmom adenosine triphosphate (ATP) and 1 U T4 DNA ligase. The total ligation reaction was then used for amplification by PCR, using the conditions described above. The inverse primers were 5'-CTCAGGGI?TCAGCCAAGGC, starting on the lower strand at position 1654 of the gp91-phox cDNA, and 5'-CCTCCGATTGACTGAGTCG, beginning at position 9 of the LTR region R. The expected product size is in excess of 220 bp, depending on the amount of flanking DNA. PCR products were separated by electrophoresis in 1.5% agarose gels and detected by Southern blotting using an overlapping 152-bp probe generated by PCR from MFGcgd plasmid DNA with the forward and inverse gp91-phox primers (positions 1503 to 1654).
For assay of NADPH oxidase activity in individual colonies, the methylcellulose was overlaid with 1 mL of 0.1% nitroblue tetrazolium (NBT), 0.9% NaCl, 1 pg/mL phorbol myristate acetate (PMA) and incubated at 37°C for 30 minutes. Positive colonies appeared blueblack due to deposition of formazan dye. For one experiment, infected bone marrow mononuclear cells were maintained in liquid culture in LTBMC medium containing 10 pmol/L 2-mercaptoethanol, 10 U/mL IL-3, and 10 U/mL G-CSF to promote expansion of myeloid precursors. Cultures were fed at weekly intervals by replacement of half of the medium and addition of fresh cytokines.
Inverse PCR ampZ$cation of integration sites.
Assay for NADPH oxidase activity in bone marrow cells.
After 3 weeks, the nonadherent cells from these bulk cultures were assayed by luminol-enhanced chemiluminescence.z0 Approximately lo6 cells were washed and resuspended in 1 mL Hanks' buffered saline solution containing 13 pmol/L luminol, 10 U/mL horseradish peroxidase. Cells were stimulated by addition of 1 pg/mL PMA. Figure 1A illustrates the progenitor transduction efficiencies obtained in 11 experiments with independent bone marrow samples. The efficiency varied between 25% and 85%, with a mean 2 SD of 49% -+ 20%. For the nine samples from healthy donors, the mean was 42% -+ 16% (range, 25% to 75%).
RESULTS
Treatment with IL-3m-6 has been reported to enhance transduction both of murine2' and human$27 bone marrow cells, and some have reported that prestimulation of target cells with cytokines leads to enhanced transduction efficien~ies.',~' We examined the effect of stimulation for 18 to 2 0 hours with IL-34L-6 and/or S C F before a 3-day coculture period in the presence or absence of the same cytokines. Prestimulation and coculture for 3 days in the presence of IL-3/IL-6 was compared with the 4-day protocol in four experiments (Fig IB) , with no significant difference in transduction efficiency. There was no difference whether the cytokines were present for either the prestimulation or coculture steps alone, or present in both steps of the protocol (data not shown). The effect of SCF and/or IL-YIL-6. was studied for both the 4-day coculture and the prestimulationl3-day coculture protocols (Fig IC) . While transduction efficiencies were similar for all cytokine combinations in the former protocol, a prestimulation step with SCF alone was detrimental ( P < .OS). In two experiments, either IL-3lIL-6 or polybrene was omitted, with no reduction in transduction efficiency (data not shown). However, increasing the polybrene concentration from 2 &mL to 4 pg/mL proved to be both toxic and detrimental to transduction: only a few poor colonies were obtained following infection. but none was provirus-positive.
While the indications from individual experiments were that each of CFU-G, CFU-M, CFU-GM, BFU-E, and CFU-GEMM could be infected, the numbers involved did not allow for accurate assessment. Summation of data for the 4-day coculture or prestimulation/3-day coculture protocols using IL-3/IL-6 showed similar progenitor transduction efficiencies for all lineages. Because there were no apparent differences between experimental variations, except when using 4 pg/mL polybrene, data from all other experiments were combined (Table I) . Progenitors of all lineages were shown to be transduced at similar efficiencies. Importantly. CFU-GM and the less committed CFU-GEMM were equally susceptible to transduction.
Validation of PCR-based assay for progenitor transduction. Because of the high transduction rates observed, it was important to validate the assay used. Negative controls included plugs of cell-free methylcellulose from experimental plates, and colonies picked following plating of noninfected bone marrow cells or cells infected with MFGnlslacz. For several experiments provirus-positive colonies were reexamined by PCR for the presence of sequences encoding hygroR, these being present in the virus producer cells, to exclude the possibility that the positive PCR signal could result from inadvertent transfer of such cells into the colony assay. No such "false-positives" were observed.
The remaining possibility for generation of artificially high transduction efficiencies is the contamination during plating or sampling of negative colonies with cells from positive colonies. The progenitor cell assay used is regarded as clonal, and only well separated colonies were picked for study. We performed a control experiment in which bone marrow cells transduced with MFGcgd were diluted with those transduced with MFGnlslacz before plating: the number of positive colonies declined with dilution, as expected. As proof of the independence of colonies scored as proviruspositive, we used inverse PCR to amplify sequences 3' to the vector integration site, for which the product size is expected to differ for independent transduction events. The colonies studied were from two experiments yielding the highest transduction efficiencies (donor D.M., using the prestimulation/cocuIture protocol with IL-3nL-6, with or without SCF; see Fig IC) Data from 10 samples using unfractionated mononuclear cells.
t Data from two samples using CD34' cells.
were scored as provirus-positive, nine of which yielded inverse PCR products. In the other case, 18 of 20 colonies were provirus-positive, 10 of which gave inverse PCR products (Fig 2) . These inverse PCR products differed for different colonies. Some colonies gave two products (eg, colonies 5, 7, and 9 of Fig 2) , indicative of multiple transduction events. This analysis confirmed the independence of the colonies scored as positive.
Trcinsditction of LTC-ICs.
In five experiments, bone marrow cells were infected by coculture using our standard protocol and subsequently maintained in LTBMC in the presence of irradiated heterologous stromal layers for LTC-IC assay. Five weeks later the nonadherent cells were plated in methylcellulose for colony formation, the majority of which were myeloid, reflecting the preference of LTBMC conditions for myelopoiesis. Figure 3 illustrates the transduction efficiency of LTC-IC, indicating that this progenitor population was targeted as efficiently as the committed progenitor compartment present in freshly isolated bone marrow. The efficiency varied between 20% and 75%. with a mean t SD of 56% If: 2 I % (56% 2 25% for the four samples from healthy donors), compared with 53% t 16% (49% If: 16%) for the progenitors from these same samples.
Infection of hone marrow CD34-positive cells. CD34' cells were obtained at purities of 90% or more by negative depletion with soybean agglutinin followed by positive selection using MoAb-coated flasks and infected by coculture with virus producer cells as for unfractionated mononucleo- cytes, use of cell-free virus with stromal support, or use of a Transwell system. In contrast to the experiments using unfractionated cells, there was some reduction in colony forming potential, especially BFU-E, of transduced CD34' cells. In two experiments transduction of CD34' cells by coculture with irradiated virus producer cells was compared with that of unfractionated mononuclear cells, in the presence of IL-3/IL-6. The progenitor transduction efficiencies were comparable (47% and 68% for CD34' cells, 25% and 75% for unfractionated cells; Fig 4) . Similar efficiencies were also obtained with CD34' cells from these donors using cell-free virus infection (six additions over 4 days) in the presence of stroma (37% and 83%; Fig 4) . For one experiment a parallel virudstroma infection was performed with the addition of IL-3/IL-6. There was no difference with or without these cytokines, for which there is likely to be endogenous expression by the stromal cells, in keeping with an earlier report in which virus was used to infect unfractionated bone marrow celk3" The third approach to infecting CD34' cells was to use the Transwell system to physically separate the virus producer and target cells, but allow passage of virus particles, with and without the addition of IL-3/IL-6. In one experiment, highly efficient transduction was obtained, dependent on the addition of cytokines. However, this was not a reliable protocol, as the efficiency in four other experi- ments was poor (0% to 25%). It may be significant that the bone marrow used in the successful experiment was derived from a X-CGD patient (A.H.) undergoing surgery for splenomegaly rather than from a healthy donor.
When analyzed by lineage. there was no indication that any of the experimental variations using CD34' cells resulted in significant differences in transduction efficiency. All lineages were represented at similar efficiencies when pooled data were analyzed (Table I ). In one experiment (D.M.) CD34' cells infected with the viridstroma protocol without exogenous cytokines were maintained in LTBMC for LTC-IC assay. Transduction of these cells (90%) was found to be as efficient as for the committed progenitors (83%).
Fiinctionnl recorisritirtion of X-CGD horie iiinrrow i d s . Individual colonies plated in methylcellulose were assessed in situ by PMA-stimulated NBT reduction. a clinical test for neutrophil NADPH oxidase function. For healthy donors. approximately half of the colonies of granulocyte morphology reduced NBT, while no colonies derived from nonmanipulated X-CGD bone marrow were positive. When infected X-CGD marrow-derived colonies were assayed. only the occasional granulocyte colony was NBT positive, despite the high efficiency of transduction determined from colonies on duplicate plates. Additionally. X-CGD bone marrow mononuclear cells were infected with either MFGcgd or MFGnlslacz, and maintained in liquid culture for a period of 3 weeks, in the presence of IL-3 and G-CSF to promote expansion of transduced granulocyte progenitors. The NADPH oxidase activity of the resultant population of cells was assayed by luminol-enhanced chemiluminescence. Cells infected with MFGnlslacz showed no response above background, while duplicate experiments with cells infected with MFGcgd both showed a PMA-dependent response, indicative of a partial restoration of function (Fig 5) . gp9I-p/iox was also detectable by Western blotting lysates of these cells (data not shown). As a control. bone marrow cells from a healthy donor were similarly infected with MFGnlslacz and maintained in liquid culture for functional assay. yielding a response with similar time course, hut a peak value more than 100-fold greater. Although the peak value cannot be regarded as a quantitative measure of 0; production. this demonstrates that the degree of reconstitution of the X-CGD marrow-derived cells was low.
DISCUSSION
We have addressed the importance of various aspects of transduction protocols for human hone marrow cells. Our initial experiments were with mononuclear cells in a 4-day coculture system with the addition of IL-3 and 1L-6. Progenitor transduction efliciencies for different samples of healthy adult bone marrow ranged from 35% to 75% (mean. 47%: Fig IA) . In contrast to the situation reported for the transduction of murine bone marrow CFU-S and marrow repopulating cells.'5 and a previous study with human bone marrow." the use of IL-YIL-6 was not required. Neither use of SCF or prestimulation with any of these cytokines enhanced transduction. Polybrene is commonly used in retrovirus transduction experiments to nonspecifically increase the effective virus titer and has been included in almost all experiments to date with both murine and human bone marrow. However.
we observed no benefit with inclusion o f 3 pg/mL polybrene. but significant toxicity and loss of transduction efficiency with 4 pg/mL.
A signilicant difference between our data and previous experiments with respect to the effect of cytokines may relate to the potentiality of the cells under consideration. Clearly murine cells capable of marrow repopulation (ie. stem cells) are more primitive than the progenitors and LTC-ICs addressed in our in vitro experiments. A further difference is that the murine experiments have used hone marrow ohtained after administration of 5-FU to donor animals. This pretreatment may generate dependence on IL-3 and IL-6 for long-term repopulation." Similarly. human stem cells Time (mins) after PMA addition For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From 3728 PORTER ET AL mobilized to the periphery following chemotherapy'" may have different growth factor requirements to those resident in the bone marrow. Another factor that complicates comparisons of different studies and may account for different reported cytokine requirements relates to the identity of the retrovirus packaging cell system used and clonal properties of derived high titer producer cells. In this regard a producer cell based on PA317 has recently been shown to be less efficient at transducing human bone marrow cells than a comparable cell based on GP + env-Aml2, owing to its production of inhibitory cytokines." Thus, it will be important to validate transduction protocols for each new vector.
Because stem cell enrichment will be a significant advantage for clinical scale-up, we compared methods for the transduction of CD34+ cells. Efficient transduction was obtained either by coculture with virus producer cells or by using cell-free virus (Fig 4) . In the latter case, transduction of LTC-IC was as efficient as committed progenitors. The cells were maintained during infection on irradiated heterologous stromal cells, and the addition of exogenous growth factors was not required. Efficient, cytokine-dependent transduction of progenitors was demonstrated for one experiment using the Transwell system, but was not reproducible. One previous study reported transduction using the Transwell system, for infecting murine cells in LTBMC,J? but a similar system failed to transduce human LTC-IC.' The important difference in the former case may be the contact between target cells and stromal cells.
Our data compare favorably with the limited published experience for the transduction of human bone marrow cells. Using the coculture system with unfractionated marrow, others have reported progenitor transduction efficiencies ranging from 20% to over 80%.4~7~y~.2"2* Similarly efficient transduction has been obtained using cell-free v i r~s . '~~~~~'~'~ We have achieved transduction efficiencies for CD34' cells comparable to those previously reported.y~".30. 43 We have validated our high transduction efficiencies by using inverse PCR to amplify integration site sequences from transduced colonies. This analysis demonstrated the independence of transduction events even in cases where the overall efficiency was as high as 90% (Fig 2) .
A significant difference between our work and previous studies is that we have shown it is possible to achieve high efficiencies without the use of polybrene or exogenous cytokines. This will be important for clinical application as potential unwanted effects that may compromise stem cell totipotentiality can be avoided. One question that has not previously been specifically addressed is whether it is possible to infect progenitor cells representative of each of the distinct hematopoietic lineages that can be studied in vitro. We addressed this for the use of unfractionated mononuclear cells or purified CD34' cells as targets and found that the lineages represented by CFU-G, CFU-M, CFU-GM, and BFU-E were infected at equal efficiencies ( Table 1) . The less committed progenitor CFU-GEMM, giving rise to mixed lineage colonies, was targeted at similar efficiency. LTC-ICs, primitive cells capable of generation of de novo progenitor cells in vitro, were also efficiently transduced in our experiments (Fig 3) , as others have rep~rted."~.'"~"'~''~ This finding is important for any protocol intended to establish a long-term therapeutic effect, but may not reflect the transduction efficiency of totipotent stem cells. The data illustrated in Fig 4 show similar transduction efficiencies for a given bone marrow source, regardless of the use of unfractionated mononuclear or purified CD34' cells, or the use of the coculture or virus/stroma protocol. However, there were marked differences in efficiency between different samples (see also Fig I) , suggesting that a major factor in the variability is intrinsic to a given bone marrow harvest. This may have significant implications for the generality of the clinical application of gene therapy using such cells.
Gene therapy for CGD could offer significant advantages over current treatment strategies, for which mortality remains high.I3 To be effective, it will be necessary not only to achieve gene transfer to a significant proportion of the stem cells but, having achieved gene transfer, to correct defective NADPH oxidase function. We have demonstrated that it is feasible to restore function by such complementation using patient-derived cell lines."." Peripheral blood CD34 ' cells from CGD patients have recently been used for gene transfer using vectors very similar to that used here."." Cells were cultured in a cocktail of cytokines to promote myeloid differentiation, and an average value of 2.5% normal activity was estimated following transfer of gp9 1 -phox, although different patients showed widely varying levels." In this paper. using a vector shown to achieve efficient gene transfer, we assessed function following expression of gp9 1 -phox in X-CGD patient bone marrow cells. Although NBT staining of plated colonies was poor, bulk populations of cells demonstrated a low, but significant, level of restored function that was appropriately regulated in response to PMA (Fig 5) . The detection of high efficiencies of progenitor transduction without noticeable effect on the colony forming potential of transduced cells indicates that this is not due to toxicity associated with the vector.
These results suggest two possibilities. Although a large proportion of CFU-G were positive for the provirus, it is possible that only a minority were capable of expression following differentiation. resulting in few NBT positive colonies and a small functional reconstitution of the bulk differentiated culture. A similar discrepancy has previously been noted between the proportion of colonies positive for provirus and those showing transcription from the LTR.' This could be a reflection of the site of provirus integration or of epigenetic repression."' An alternative possibility is that all differentiated cells were capable of low levels of expression, this proving adequate in only a minority of cases for the insensitive assay of NBT reduction by individual colonies. Our results suggest that a gene therapy approach to the management of CGD will be feasible, but highlight the need to give attention to attaining adequate levels of gene expression following transfer to hematopoietic cells.
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